The PLAC® Test is a diagnostic test that measures the amount of Lp-PLA2, an enzyme involved in the formation of rupture-prone arterial plaque, in the blood. Patients with high blood levels of this enzyme have a significantly higher risk of suffering a heart attack or stroke.
It is known that arterial plaque rupture and not stenosis causes most heart attacks and death from cardiac causes. A key feature of Lp-PLA2 is that levels of this enzyme are significantly and specifically increased in plaque that is prone to rupture.
Measurement of Lp-PLA2 is recognized by the American Heart Association and the American College of Cardiology Foundation as helpful for the assessment of cardiovascular risk and primary prevention of stroke. Furthermore, the PLAC® Test is the only test that has been approved by the FDA for this purpose.
Routinely measured cardiac biomarkers, including LDL-cholesterol, have not proven to be reliable predictors of stroke. The PLAC® Test addresses this important unmet clinical need in identifying patients who may benefit from more aggressive treatment. To learn more about the Lp-PLA2 mechanism of action, download our overview document here.
For more information about the PLAC Test, contact us today!
To view our PLAC Test National Advisory Board, please visit this page.
Davidson et al, 2008. Consensus Panel Recommendation for Incorporating Lipoprotein-Associated Phospholipase A2 Testing into Cardiovascular Disease Risk Assessment Guidelines. American Journal of Cardiology; 101 [suppl]: 51F-57F.